The THIO-101 patient with 30-month survival received therapy every three weeks, and concluded treatment upon reaching the maximum treatment duration of 2 years based on protocol requirements. MAIA’s ...
Outstanding measure of efficacy relative to high-risk cancers with limited treatment options CHICAGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA", the "Com ...
Background The life-long exposure of the left heart chambers to systemic blood pressures may be important to changes in left ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback